PARP Inhibitors in Ovarian Cancer

E-ISSN： 2212-3970|13|4|392-410

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.13, Iss.4, 2018-11, pp. : 392-410

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer

International Journal of Oncology, Vol. 43, Iss. 2, 2013-01 ,pp. : 513-520

Spandidos Publications

Access to resources Recommend Favorite

Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells

Oncology Reports, Vol. 33, Iss. 5, 2015-01 ,pp. : 2199-2206

Spandidos Publications

Access to resources Recommend Favorite

Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice

Oncology Letters, Vol. 4, Iss. 6, 2012-01 ,pp. : 1269-1273

Spandidos Publications

Access to resources Recommend Favorite

Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review

By Kobayashi Masaki Sawada Kenjiro Kimura Tadashi

Cancers, Vol. 9, Iss. 7, 2017-07 ,pp. : 83-83

MDPI

Access to resources Recommend Favorite

PARP Inhibitor Development for Systemic Cancer Targeting

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 7, Iss. 5, 2007-09 ,pp. : 515-523

Bentham Science Publishers

Access to resources Recommend Favorite